Study of TOP1630 for Dry Eye Syndrome
NCT03833388
·
clinicaltrials.gov ↗
PHASE2,PHASE3
Phase
COMPLETED
Status
202
Enrollment
INDUSTRY
Sponsor class
Conditions
Dry Eye Syndrome
Interventions
DRUG:
TOP1630 0.1% Ophthalmic Solution TID OU
DRUG:
Placebo to TOP1630 0.1% Ophthalmic Solution TID OU
Sponsor
Topivert Pharma Ltd